EP 60: The Year 2021 in Review with Dr Sukh Nijjer – Part 1
In the last Parallax episode of the year,Dr Ankur Kalra welcomed back Dr Sukh Nijjer, Interventional Cardiologist from Imperial College London, to review the most impactful events and advances in cardiology from 2021.
This year we had a number of studies that helped clarify our understanding of the world of antiplatelets: First, Ankur and Sukh discuss the take-home messages from HOST-EXAM, a Korean study presented at ACC 2021. They discuss their clinical experiences within the UK and US setting. Next, Sukh talks about the STOPDAPT-2 ACS study, presented at ESC 2021. Sukh interprets the findings in the light of TWILIGHTand summarises his thoughts on the therapy.
2021 was not a great year for physiology: Sukh shares his take on FLOWER-MI, presented at ACC 2021. He offers a deep dive into the data and highlights both the importance of the findings and the limitations of the study.
Next, they discuss RIPCORD 2 from ESC 2021 and finally, Sukh highlights the findings from the FAME 3 trial.
What is the importance of genotype testing in the world of antiplatelets? What are the considerations for clinicians? Should we stop using FFR? How can we incorporate novel findings to patient care? What are the practical considerations that we should take into account when looking at the physiology trials of 2021?
Stay tuned for Part 2 - heart failure and surgical trials coming in 2022.
Questions and comments can be sent to “podcast@radciffe-group.com” and may be answered by Ankur in the next episode. Guest @SukhNijjer, hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Read MoreRead Less
Brought to you by Edwards: www.edwardstavr.com
Read MoreRead Less
EP 61: The Year 2021 in Review with Dr Sukh Nijjer — Top Trials in Heart Failure and Cardiac Surgery
In the second part of Parallax’s review of 2021, Dr Sukh Nijjer, Interventional Cardiologist from Imperial College London, and Dr Ankur Kalra discuss key advances in the field of heart failure and cardiac surgery.
Read More
All Episodes
We have observed a lot of developments in percutaneous coronary intervention (PCI) over the past 12 months with the publication of various studies and trials. This week, Ankur spoke with J. Dawn Abbott, MD, Associate Professor of Cardiology at Warren Medical School of Brown University about her recently published US Cardiology Review 13.1 article on the significant developments in PCI over the past 12 months.
Dawn is an associate editor of the journal Circulation: Cardiovascular Interventions and is widely known for her research program on PCI and peripheral arterial disease (PAD). Ankur and J. Dawn discuss multiple trials/studies that were published in 2018, including ORBITA, PIONEER-II and ABSORB. J. Dawn also shares her thoughts on the latest stent technologies.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
Dawn is an associate editor of the journal Circulation: Cardiovascular Interventions and is widely known for her research program on PCI and peripheral arterial disease (PAD). Ankur and J. Dawn discuss multiple trials/studies that were published in 2018, including ORBITA, PIONEER-II and ABSORB. J. Dawn also shares her thoughts on the latest stent technologies.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
This week’s podcast guest needs no introduction! Prof Athena Poppas is one of the most widely known cardiologists in the US and current Vice-President of the American College of Cardiology! Ankur spoke to Athena about her recently published US Cardiology Review 13.1 article on whether early management of hypertension by GPs can improve outcomes.
They discuss the importance of preventative medicine, their experience of reducing hypertension with non-pharmaceutical and pharmaceutical methods, and the significance of the integrated “team approach” when treating comorbid conditions such as hypertension. Athena also shares her thoughts on cardiologists’ responsibility to shape their patients’ lifestyle choices.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
They discuss the importance of preventative medicine, their experience of reducing hypertension with non-pharmaceutical and pharmaceutical methods, and the significance of the integrated “team approach” when treating comorbid conditions such as hypertension. Athena also shares her thoughts on cardiologists’ responsibility to shape their patients’ lifestyle choices.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Ankur is back with his second #AudioArticle! This week he spoke with Santiago Garcia from the Minneapolis Heart Institute about Santiago’s US Cardiology Review 13.1 article on the role of high-sensitivity cardiac troponin (hscTn) assays and their ability to rapidly rule in or rule out acute coronary syndrome (ACS) with improved sensitivity.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
In our first episode, Ankur explains his vision for and inspiration to start ‘Parallax’, and speaks with Chad Kliger from Lenox Hill Hospital in New York about conduction abnormalities after transcatheter aortic valve replacement (TAVR/TAVI), a review article published in US Cardiology Review 13.1 Ankur and Chad look at conduction abnormalities after TAVR/TAVI with a focus on basic conduction system anatomy in relation to the aortic valve, the mechanism, incidence, predisposing factors for occurrence, impact on mortality and finally, proposed treatment algorithms for management. Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
In this week’s episode Ankur Kalra asks Dr Suzanne J Baron, Director of Interventional Cardiovascular Research at Lahey Hospital & Medical Center: How do we measure the value of a novel technology?
During her interventional cardiology fellowship, Dr Baron became fascinated by the implementation of novel technologies. She earned her degree in Clinical Epidemiology and spent a year working at the FDA’s Device Evaluation unit.
In 2019 Dr Baron presented the results of her late-breaking trial, COAPT. Ankur invites Suzanne to discuss the economic analysis of the study and to give a short introduction to cost-effectiveness analysis. Suzanne provides an overview of the trial and they talk about the importance of understanding the value and benefits of new devices from both the patient and the health-economic point of viewpoint.
Read More
During her interventional cardiology fellowship, Dr Baron became fascinated by the implementation of novel technologies. She earned her degree in Clinical Epidemiology and spent a year working at the FDA’s Device Evaluation unit.
In 2019 Dr Baron presented the results of her late-breaking trial, COAPT. Ankur invites Suzanne to discuss the economic analysis of the study and to give a short introduction to cost-effectiveness analysis. Suzanne provides an overview of the trial and they talk about the importance of understanding the value and benefits of new devices from both the patient and the health-economic point of viewpoint.
In this week’s Parallax, host Ankur Kalra is joined by Charles (Chuck) Simonton, Vice President and Chief Medical Officer of Abiomed. Chuck talks about how his father’s leadership and service as a Methodist minister inspired him to become a doctor. He recalls the dawn of interventional cardiology: the birth of angioplasty and stenting. Drawing from his experiences as a trialist who worked with some of the most influential minds, he offers practical tips to young doctors. Finally, Ankur asks Chuck about the Impella device controversy and the recent decision of Abiomed to accelerate their clinical research.
How should you start building a research programme? What are Chuck Simonton’s thoughts on the relationship between doctors and the industry? What is Chuck’s message to young cardiologists?
Read More
How should you start building a research programme? What are Chuck Simonton’s thoughts on the relationship between doctors and the industry? What is Chuck’s message to young cardiologists?
Martha Gulati, Professor of Medicine and the Chief of Cardiology at the University of Arizona joins Ankur Kalra to continue the important conversation on how the cardiovascular community can stand up against sexism.
After the #MedBikini campaign provoked by a misogynistic study that scrutinized female doctors’ social media posts, this episode is about creating a safer environment for female healthcare professionals.
Read More
After the #MedBikini campaign provoked by a misogynistic study that scrutinized female doctors’ social media posts, this episode is about creating a safer environment for female healthcare professionals.
This week’s guest, Prof Roxana Mehran, Professor of Medicine at Mount Sinai and Founding Director of Women as One, is a phenomenon in interventional cardiology. Her pioneering work as clinician, trialist and advocate is well known within the community. In this episode, we learn what makes Roxana tick and what were the odds she had to defy as an immigrant from Iran to fulfil her ‘impossible dream’.
The charity organisation, Women as One is an agent for women and men to be part of medicine that is built on talent, rather than a privilege. Roxana and Ankur discuss the role of mentorship and family-friendly work environment in mending the broken house of cardiology. Roxana talks about the practical tools that are available for women to take the next steps in their career and achieve their goals.
Read More
The charity organisation, Women as One is an agent for women and men to be part of medicine that is built on talent, rather than a privilege. Roxana and Ankur discuss the role of mentorship and family-friendly work environment in mending the broken house of cardiology. Roxana talks about the practical tools that are available for women to take the next steps in their career and achieve their goals.
This week’s guest is Dr Laura Mauri who became Vice President of Global Clinical Research and Analytics at Medtronic in 2018 after an illustrious career in academic medicine at Brigham and Women’s Hospital and Harvard Medical School.
Dr Kalra asks Dr Mauri about early influences and her traineeship with legendary interventionalists, the late Donald Baim and Richard Kuntz. Dr Mauri talks openly about her decision-making process and the importance of selecting your priorities and committing to them. Ankur asks Laura about her decision to go into industry. Laura shares her thoughts on medical innovations and meeting urgent needs with unique perspectives.
What is Dr Mauri’s advice for a young cardiologist? How did she balance research and patient care? What are the questions that helped her decision making? How does Dr Mauri think about innovations in medicine?
Read More
Dr Kalra asks Dr Mauri about early influences and her traineeship with legendary interventionalists, the late Donald Baim and Richard Kuntz. Dr Mauri talks openly about her decision-making process and the importance of selecting your priorities and committing to them. Ankur asks Laura about her decision to go into industry. Laura shares her thoughts on medical innovations and meeting urgent needs with unique perspectives.
What is Dr Mauri’s advice for a young cardiologist? How did she balance research and patient care? What are the questions that helped her decision making? How does Dr Mauri think about innovations in medicine?